Biotech

All Articles

Merck ceases period 3 TIGIT test in lung cancer cells for futility

.Merck &amp Co.'s TIGIT plan has gone through yet another setback. Months after shuttering a stage 3...

After a tough year, Exscientia folds up in to Recursion

.After a year specified by pipeline hairstyles, the departure of its own chief executive officer as ...

Cullinan, after $25M bargain, return bispecific to Harbour

.Cullinan Therapeutics was actually blown away sufficient with Harbour BioMed's bispecific immune sy...

A deeper look at Fierce Biotech's Strong 15

.Within this week's episode of "The Leading Pipe," our company are actually diving in to Intense Bio...

Lilly faces phase 2 failing of tau-targeting med

.The confetti is still soaring from Eli Lilly's celebration commemorating the approval of Alzheimer'...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Welcome to recently's Chutes &amp Ladders, our roundup of significant leadership hirings, firings a...

Lykos will definitely ask FDA to reexamine its own selection following being rejected of MDMA therapy for trauma

.Following a poor revealing for Lykos Rehabs' MDMA candidate for post-traumatic stress disorder at a...

AN 2 fifty percents census, ceases phase 3 trial after data disappoint

.AN2 Rehabs is actually reconsidering its business in reaction to dull midphase records, promising t...

Merck pays out $700M for bispecific, spying autoimmune opening and also possibility to test Amgen in cancer cells

.Merck &amp Co. is actually paying out $700 thousand beforehand to challenge Amgen in a blood stream...

Gilead pays J&ampJ $320M to leave licensing package for seladelpar

.With Gilead Sciences almost an FDA choice for its own liver health condition drug seladelpar, the c...